Form 8-K - Current report:
SEC Accession No. 0001171843-25-005405
Filing Date
2025-08-14
Accepted
2025-08-14 07:35:28
Documents
14
Period of Report
2025-08-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K f8k_081425.htm   iXBRL 8-K 15804
2 PRESS RELEASE exh_991.htm EX-99.1 26231
  Complete submission text file 0001171843-25-005405.txt   245795

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE gnw-20250101.xsd EX-101.SCH 3402
4 XBRL DEFINITION FILE gnw-20250101_def.xml EX-101.DEF 26066
5 XBRL LABEL FILE gnw-20250101_lab.xml EX-101.LAB 35956
6 XBRL PRESENTATION FILE gnw-20250101_pre.xml EX-101.PRE 24702
16 EXTRACTED XBRL INSTANCE DOCUMENT f8k_081425_htm.xml XML 3425
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 212-994-8250
MiNK Therapeutics, Inc. (Filer) CIK: 0001840229 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40908 | Film No.: 251214365
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)